What does Bexagliflozin (Brenzavvy) do in plain English—and how does it work inside your body?
Bexagliflozin is an FDA-regulated Sodium-Glucose Cotransporter 2 Inhibitor (RxNorm RxCUI 2637859). Mechanistically, 12.1 Mechanism of Action Bexagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorption of the majority of glucose from the renal glomerular filtrate in the renal proximal tubule. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. [1][2].
When your doctor writes a prescription for Bexagliflozin (RxNorm RxCUI 2637859, also dispensed under brand names including Brenzavvy), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, 12.1 Mechanism of Action Bexagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorption of the majority of glucose from the renal glomerular filtrate in the renal proximal tubule. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. [2].
Across real-world patient logs on dotMD (86% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Bexagliflozin tablet bottle and confirm with your pharmacist that it matches your prescribed strength (20 mg/1 Tablet, 20 mg once daily, 30 mL).